Compare McCormick & Company, Incorporated (MKC) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs Health Care Select Sector SPDR Fund — how do they compare? McCormick & Company, Incorporated trades at $45.42 (market cap $12.39B), while Health Care Select Sector SPDR Fund trades at $169.61 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is far larger — about 3.5× McCormick & Company, Incorporated's market cap, and McCormick & Company, Incorporated pays a 4.18% dividend while Health Care Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold McCormick & Company, Incorporated for 67 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| MKC | XLV | |
|---|---|---|
Market Cap | $12.39B | $43.48B |
Volume | 6,140,872 | 11,121,431 |
Sector | Consumer Staples | — |
52-Week High | $71.65 | $175.68 |
52-Week Low | $44.14 | $141.95 |
Typical Hold Time | 67 Days | 100 Days |
Enterprise Value | $17.07B | — |
Dividend Yield | 4.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKC trades at $45.25, down 0.33% on the day, with a bearish technical signal but attractive valuation metrics including a P/E of 8.31. The company reported strong Q3 2026 earnings of $0.86 per share, beating estimates, driven by 17% sales growth and margin expansion. Recent dividend declaration of $0.48 per share provides income support. Revenue growth has been steady, reaching $6.84B in 2025 with net income of $789.4M.
The stock presents value opportunity with below-sector P/E ratio and consistent profitability (19.39% net margin), though technical indicators signal near-term weakness. Analyst consensus is mixed with 33% buy ratings but $53.50 price target suggests 18% upside. Key risks include integration challenges from acquisitions and consumer spending sensitivity.
XLV trades at $168.81, up 1.03% today, with a bullish technical signal driven by moving averages. The ETF holds 61 healthcare stocks from the S&P 500, offering broad sector exposure at a low 0.08% expense ratio. Recent news highlights its defensive appeal amid market volatility and potential Fed rate hikes, with articles comparing it favorably to peers like IBB and PJP on cost and diversification.
Outlook is positive given healthcare's defensive growth profile and XLV's cost efficiency, but risks include political uncertainty from midterm elections and sector-specific volatility from drug trial outcomes. Wall Street sentiment is constructive, with the ETF near key resistance at $170.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
